Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Equity Average (2016 - 2025)

Historic Equity Average for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Q3 2025 value amounting to $767.1 million.

  • Amphastar Pharmaceuticals' Equity Average rose 646.79% to $767.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $767.1 million, marking a year-over-year increase of 646.79%. This contributed to the annual value of $685.9 million for FY2024, which is 1743.38% up from last year.
  • Amphastar Pharmaceuticals' Equity Average amounted to $767.1 million in Q3 2025, which was up 646.79% from $754.4 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Equity Average's 5-year high stood at $767.1 million during Q3 2025, with a 5-year trough of $437.8 million in Q4 2021.
  • Over the past 5 years, Amphastar Pharmaceuticals' median Equity Average value was $568.9 million (recorded in 2023), while the average stood at $586.6 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Equity Average crashed by 266.62% in 2021, and later surged by 2178.66% in 2024.
  • Over the past 5 years, Amphastar Pharmaceuticals' Equity Average (Quarter) stood at $437.8 million in 2021, then increased by 18.06% to $516.9 million in 2022, then grew by 19.42% to $617.3 million in 2023, then increased by 18.26% to $730.0 million in 2024, then rose by 5.09% to $767.1 million in 2025.
  • Its Equity Average stands at $767.1 million for Q3 2025, versus $754.4 million for Q2 2025 and $741.8 million for Q1 2025.